He was diagnosed with incurable blood cancer in 2009
An RAF Air Vice Marshal and former Red Arrows Group Captain has embarked on a 3,200-mile race across the Sahara Desert in aid of Myeloma UK, which is a charity close to his heart.
Fin and his crew have battled their way along the original Dakar Rally route, across thousand miles of sand, rock and gravel through Morocco – all in scorching heat – before reaching the finish line before the end of the October.Fin set off on October 13 and completed the challenge before the end of October.The money will go to Myeloma UK, a charity dedicated to funding vital research into new treatments and, ultimately, a cure.
Over the years he has raised thousands of pounds for Myeloma UK in a bid to improve diagnosis, make sure the disease is caught sooner and give future patients the best possible chance at living a fulfilling life.He said: “Our vehicle had over 130,000 miles on the clock when we started. It was painted up to resemble the iconic Spitfire and Lancaster aircraft of the Second World War and to reflect that all four of us are RAF pilots as well as adventurers.The view from Fin and the team’s ‘banger’.
France Dernières Nouvelles, France Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
Red Arrows flying suit and hand-painted vase in Lincoln Mayor's charity auctionThe auction will take place at 6pm this evening so get ready with your bids Lincoln
Lire la suite »
Embracer Group shuts down former Square Enix Montréal studioEmbracer Group is closing its down Square Enix Montréal studio - which it purchased as part of a $300m USD deal …
Lire la suite »
Phillies mash 5 HRs in Game 3 win over AstrosPHILADELPHIA — They wore red caps and jerseys with red pinstripes, with red hoodies and red beanies to ward off the chill. They held signs with red lettering and waved red towels until their shoulders tired. For three hours and eight minutes on Tuesday — plus a good while before and after the...
Lire la suite »
Phillies mash 5 HRs, take WS lead in front of raucous crowdPHILADELPHIA — They wore red caps and jerseys with red pinstripes, with red hoodies and red beanies to ward off the chill. They held signs with red lettering and waved red towels until their shoulders tired. For three hours and eight minutes on Tuesday — plus a good while before and after the...
Lire la suite »
Naltrexone-Bupropion and Behavior Therapy, Alone and Combined, for Binge-Eating Disorder: Randomized Double-Blind Placebo-Controlled TrialObjective: Binge-eating disorder, the most prevalent eating disorder, is a serious public health problem associated with obesity, psychiatric and medical comorbidities, and functional impairments. Binge-eating disorder remains underrecognized and infrequently treated, and few evidence-based treatments exist. The authors tested the effectiveness of naltrexone-bupropion and behavioral weight loss therapy (BWL), alone and combined, for binge-eating disorder comorbid with obesity. Methods: In a randomized double-blind placebo-controlled trial conducted from February 2017 to February 2021, using a 2×2 balanced factorial design, 136 patients with binge-eating disorder (81.6% women; mean age, 46.5 years; mean BMI, 37.1) were randomized to one of four 16-week treatments: placebo (N=34), naltrexone-bupropion (N=32), BWL+placebo (N=35), or BWL+naltrexone-bupropion (N=35). Overall, 81.7% of participants completed independent posttreatment assessments. Results: Intention-to-treat binge-eating remission rates were 17.7% in the placebo group, 31.3% in the naltrexone-bupropion group, 37.1% in the BWL+placebo group, and 57.1% in the BWL+naltrexone-bupropion group. Logistic regression of binge-eating remission revealed that BWL was significantly superior to no BWL, and that naltrexone-bupropion was significantly superior to placebo, but there was no significant interaction between BWL and medication. Mixed models of complementary measures of binge-eating frequency also indicated that BWL was significantly superior to no BWL. The rates of participants attaining 5% weight loss were 11.8% in the placebo group, 18.8% in the naltrexone-bupropion group, 31.4% in the BWL+placebo group, and 38.2% in the BWL+naltrexone-bupropion group. Logistic regression of 5% weight loss and mixed models of percent weight loss both revealed that BWL was significantly superior to no BWL. Mixed models revealed significantly greater improvements for BWL than no BWL on secondary measures (eating disorder psych
Lire la suite »